Health Care Archives - Page 20 of 478

2 minute read

Attention Biotech Investors – Stocks To Watch

May 16, 2:21 PM

RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.

AGIO

2 minute read

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

By Vandana Singh

May 16, 12:35 PM

Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.

JNJ

2 minute read

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate

By Vandana Singh

May 16, 12:31 PM

Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with mild to moderate adverse events.

RHHBY

2 minute read

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another

By Vandana Singh

May 16, 12:11 PM

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.

BIIB

1 minute read

FDA Approves Expanded Use Of Bristol Myers Squibb’s Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma

By Vandana Singh

May 16, 11:56 AM

FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.

BMY

1 minute read

AstraZeneca’s COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows

By Vandana Singh

May 16, 11:34 AM

AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.

AZN

2 minute read

Eli Lilly’s Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show

By Vandana Singh

May 16, 10:13 AM

Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes.

LLY

2 minute read

Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report

By Benzinga Neuro

May 16, 3:04 AM

In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 million.

PFE

2 minute read

Integer Can Drive Consolidation Of Medical Device Outsourcing, Bullish Analyst Projects

By Vandana Singh

May 15, 3:19 PM

Truist Securities initiates coverage on Integer. With a Buy rating and a $137 target, Integer is poised for significant gains driven by organic growth and strategic acquisitions.

ITGR

2 minute read

Boston Scientific’s Upside With Cardiology Devices Drives Momentum

By Vandana Singh

May 15, 3:02 PM

Mizuho Securities raises target for Boston Scientific, predicting double-digit growth in cardiology. Surge in Farapulse adoption and Watchman FLX upside driving momentum.

BSX